TGF-β1 and Smad7 in the regulation of IBD · TGF-β1 and Smad7 in the regulation of IBD Giovanni...
Transcript of TGF-β1 and Smad7 in the regulation of IBD · TGF-β1 and Smad7 in the regulation of IBD Giovanni...
FALK WORKSHOPMechanisms of intestinal inflammation
Dresden October 9-10, 2007
TGF-β1 and Smad7 in the regulation of IBD
Giovanni MonteleoneDept of Internal Medicine
UNIVERSITY TOR VERGATA
OF ROME
TGF-β1 is a negative regulator of mucosal inflammation
• TGF-β1 null mice die of inflammation, including the gut
• Transgenic mice expressing a dominant-negative TGF-βRII chain develop severe colitis and pulmonary inflammation
• In mouse models of IBD, synthesis of TGF-β1 associates with either the protection from the development of colitis or greatly diminished severity of colitis
Activated TGF-β1 is produced in the human normal gut
Ileal and colonic biopsies taken from 5 normal subjects
pg/1
00 μ
g to
tal p
rote
ins
50
40
30
20
10
0Ileum colon
TGF-β1 transcripts in laser captured epithelium (E) and lamina propria (LP) mononuclear cells from normal ileum and colon
5 samples in each group
TGF-
βtr
ansc
ripts
(rel
ativ
e un
its)
0
20
40
60
80
100
10
30
50
70
90
E LP E LP
Ileum
Colon
Adapted from Smythies LE et al. JCI 2005; 115: 66
Mast cells, not macrophages, are an intestinal source of TGF-β
TGFβ-producing LPMC C-kit-positive cells
HAM56-positive cells TGFβ-producing epithelial cells
•
T-be
t/β-a
ctin
(a.u
.)
IgG aTGFβ02
64
810
1412 p<0.0001
02
64
IgG aTGFβ
810
1412 p<0.0001
Mucosa
IgGPatient 1 Patient 2
aTGFβT-bet
β-actin
LPMC
Blockade of TGF-β1 in cultures of normal colon LPMC or mucosal explants increases the Th1 transcription factor T-bet and IFN-γ
IFN
-γ(p
g/m
l)
p=0.005
0
40
80
120
160
••••
••
•
•
•
•
•
•
•
•
• •••
•
p=0.020
0
2040
60
100
80
• •• •• •• ••
••
•
• ••
•
••
•
T-be
t/β-a
ctin
(a.u
.)
IgG aTGFβ
IgGPatient 1 Patient 2
aTGFβ IgG aTGFβT-bet
β-actin
IFN
-γ(p
g/m
l)
IgG aTGFβ
IgG aTGFβ
0
300
600
900
1200
1500
1800
2100
IgG aTGFβ IgG aTGFβ IgG aTGFβ
IL-17
p=0.024p=0.047
IL-8
p=0.002
Cytokine production by LPMCs(pg/ml)
0
5
10
15
20
25
IL-2
0
5
10
15
20
25
••
30
35
40
••• •
• •••
•
•
•
•
• ••
•••
•
•
••
• •
•• •
30
35
40
•
•
••
•
• •••
• ••
•
Blockade of TGF-β1 in cultures of normal intestinal LPMCincreases the secretion of inflammatory cytokines
Blockade of endogenous TGF-β1 in cultures of normal LPMC does not affect the percentage of Foxp3-positive cells
CD4
Foxp
3
CD4
Foxp
3
IgG anti-TGF-β0,15% 0,35%
60,8% 38,7%
0,32% 0,34%
69 % 30,3%
3
2
1
0% F
oxp3
+ C
D4+
LP
L
IgG anti-TGF-β(3 days culture)
TNF - + + + + + +TGF-β1 - - + - - - -NF-kB/p65 ab - - - + - - -NF-kB/p50 ab - - - - + - -excess of specific probe - - - - - + -excess of non specific probe - - - - - - +
P50 homodimerP65/p50 heterodimer
TGF-β1 inhibits TNF-induced NF-kB DNA binding activityin normal lamina propria mononuclear cells
4
3
2
1
0 ActiveCD
InactiveCD
ActiveUC
InactiveUC
Normal
Adapted from Babyatsky et al, Gastro 1996; 110:975
Enhanced TGF-β RNA expression in the inflamed colonic mucosa of patients with Crohn’s disease and patients with ulcerative colitis
TGF-
β/G
AP
DH
Real-time PCR analysis
Blockade of TGF-β1 in cultures of CD mucosal explants does not affect the expression of T-bet
T-be
t RN
A re
lativ
e ex
pres
sion 2,0
1,5
1,0
0,5
0IgG anti-TGF-β
P50 homodimer
P65/p50 heterodimer
NF-kB/p65
Medium + - -TNF - + +TGF-β1 - + +
Histone-1
NF-kB activation is barely decreased by TGF-β1 in IBD LPMC
IIIP
P
TGFβ1
Smad2/3
Smad4
DNA
Target gene
TGFβ signalling through Smads
P
P
P-SMAD3
SMAD3
SMAD3-boundSMAD4
Controls CD UC
Active SMAD3 is down-regulated ininflammatory bowel disease mucosa-biopsies
P
P
III P
TGFß1
Smad2/3
Smad4
Monteleone G, et al. J Clin Invest 2001; 108:601-9
SMAD7
controls1 2 3 1 2 3
CD1 2 3
UC
CD UC C CD UC C
non CD3+
SMAD7
CD3+
Increased SMAD7 in inflammatory bowel disease mucosa
TGFß
III PSmad2/3
Smad7
Monteleone G, et al. J Clin Invest 2001; 108:601-9
-
+ + +
U S AS SMAD7
P-SMAD3
SMAD3
Crohn’s disease
Smad7 anti-sense (AS) inhibits Smad7 and restores TGF-β signalling
IIIP
TGFβ
Smad2/3
P
Smad7
Smad3
U S AS
TGF-β
Crohn’s disease
Monteleone G, et al. J Clin Invest 2001; 108:601-9
TNF
SEB +
0
10000
20000
30000
40000
50000
0 0,1 1 10
trans
crip
ts/μ
g to
tal R
NA
mediumsenseantisense
TGF-β1 (ng/ml)
Anti-sense to Smad7 allows TGF-β1 to inhibitTNF transcripts in Crohn’s
Monteleone G, et al. J Clin Invest 2001; 108:601-9
SMAD7
p-SMAD3
SMAD3
TNF-α
IFN-γ
medium sense antisense
IFN
-γ(p
g/μg
tiss
ue) 750
500
250
medium sense antisense
SMAD7 antisense restores TGF-β1 signaling and inhibitscytokine production in Crohn’s disease (CD) tissue
CD tissue culture supernatants
CD tissue
Question?
What induces Smad7 in IBD?
TGF-β1
P
P
STAT1Smad7
nucle
us
Smad7 gene promoter
IFN-γ
p-STAT1
NF-kB
TNF-α
IFN-γ/STAT1 and TNF/NF-kB induce SMAD7 RNA expression in cell lines
Smad7 RNA
p-Tyr-STAT1
Inhibition of either STAT1 or NF-kB activationdoes not change SMAD7 protein expression in CD
LPMC UNST TPCK Vehicle
NuclearNF-kB/p65
Histone-1
Smad7
β-actin
N-p-Tosyl-L-phenylalaninechlorometyl ketone (TPCK) =
NF-kB inhibitor
Smad7
β-actin
STAT1βSTAT1α
UNST TB42 Vehicle
Tyrphostin B42 (TB42) =JAK2/STAT1 inhibitor
Paired biopsies from IBD and normals
Smad7: real time RT-PCR and Western blotting
To examine the molecular mechanisms underlying the induction of Smad7 in human intestine
transcriptionally or post-transcriptionally regulated?
Sm
ad7/
β2-m
icro
glob
ulin
RN
A
(f.u.
x 10
-7)
0
2,5
5
7,5controls
1 2 3 4 Crohn’s disease
61 KD50 KD
38 KD
50 KD
38 KD
Smad7 protein but not RNA is increased in IBD mucosa
Smad7
β-actin
1 2 3 4
Smad7
β-actin
controls1 2 3 4
Crohn’s disease1 2 3 4
controls CD UC
Real-time PCR data
In IBD, Smad7 is regulated at the post-transcriptional level
Is the high Smad7 due to:
• enhanced de novo protein synthesis
• increased stability of the protein
Question?
1,5 1,5 3 3 6 6- + - + - +
Smad7hours
IkBα
β-actin
Per
cent
age
of re
mai
ning
prot
ein
afte
r CH
X
0 1,5 3 6 Time (h)
100
50
0
Smad7IkBα
CD LPMCbasal CHX
Normal LPMC
In IBD, high Smad7 does not relyon a sustained protein synthesis
1,5 1,5 3 3 6 6- + - + - +
hours
basal CHX
Smad7β-actin
Is the high Smad7 due to:
• enhanced de novo protein synthesis
• increased stability of the protein
Question?
Smad7 degradation
Smad7
Arkadia
JAB1
ubiquitin
proteasome
Checkpoints in the control of Smad7 protein stability
- - +
1 2 3
0 3 5 7 0 3 5 7
IP: Smad7Blot: ubiquitin ab
Crohn’s disease controls ve -1 2 3
IP: Smad7Blot: Smad7
Smad7β-actin
control CD Hrs of incubation
0 5 5 Hrs of incubationProteasome
inhibitors
Ubiquitination and degradation of Smad7occur in controls but not Crohn’s disease (CD)
control
Smad7β-actinMonteleone G, et al. Gastroenterology 2005; 129: 1420
Normal LPMCMG132+
UNS MG115 dmso
CD LPMC
Inhibition of the proteasome pathway enhances Smad7 protein expression in normal intestinal LPMC
Smad7
β-actin
MG132+MG115= proteasome inhibitors
MG132+UNS MG115 dmso
Smad
7/β-
actin
prot
ein
(a.u
.)
MG132+UNS MG115 DMSONormal LPMC
MG132+UNS MG115 DMSO
CD LPMC
0
0,3
0,6
0,9
1,2
Smad7 degradation
Smad7
Arkadia
JAB1ubiquitin
proteasome
Smad7
acetylationAcetylated
Smad7ubiquitin
Control of SMAD7 stability by competitionbetween acetylation and ubiquitination
Acetylated- Smad7ns
Total Smad7
Smad7 is acetylated in IBD
1 2 CDcontrols ve -
1 2 1 2 UC
0
0,25
0,5
0,75
1
controls CD
Ace
tyla
ted/
tota
l Sm
ad7
(a.u
.)
UC
P=0.001
P=0.02
P= NS
Monteleone G, et al. Gastroenterology 2005; 129: 1420
Smad7 degradation
Smad7
Arkadia
JAB1ubiquitin
proteasome
Smad7
acetylationAcetylated
Smad7ubiquitin
Control of SMAD7 stability by competitionbetween acetylation and ubiquitination
ROLE OF p300
p300
p300IP: Smad7blot: p300 ab
Smad7IP: Smad7blot: Smad7 ab
p300 interacts with Smad7 in CD
1 2 3Crohn’s disease controls ve -
1 2 3
p300
p300
IgG
IgG
CD
Con
trol
Monteleone G, et al. Gastroenterology 2005; 129: 1420
Inhibition of p300 by siRNAreduces Smad7 expression in CD
control p300Uns siRNA siRNA
p300
CD LPMC
β-actin
control p300Uns siRNA siRNA
ve -
acetylated Smad7
Ubiquitinated Smad7
CD LPMC
Smad7β-actin
control p300Uns siRNA siRNA
CD LPMC
Monteleone G, et al. Gastroenterology 2005; 129: 1420
What is the functional role of Smad7 inmurine models of IBD?
Question?
TNBS-colitis (Crohn’s disease-like colitis)
oxazolone-colitis (which resembles Ulcerative colitis)
naive EtOH TNBS
Smad7
β-actin
p-Smad3
Smad3
High TGF-β1 associates with a diminished p-Smad3 and enhanced Smad7 expression in TNBS-induced colitis
0
200
400
600
800
naive EtOH TNBS
TGF-β1pg/100 μg total proteins
naive EtOH TNBSCD3+
CD3-
LPMC
naive EtOH TNBS
Sm
ad7
1 2naive Oxa
1 2Smad7
β-actinp-Smad3
Smad3
1
10
100
1.000
10.000
naive Oxa
TGF-β1pg/100 μg total proteins
High TGF-β1 associates with a diminished p-Smad3 and enhanced Smad7 expression in oxazolone-induced colitis
1 2naive Oxa
1 2
Administration of Smad7 antisense oligonucleotide in mice with experimental colitis
days
SJL mice
Intrarectal administration of 150 μl of Ethanol 50%
or ethanol 50% + TNBS or oxazolone
Histology andProtein analysis
0 1 2 3 4
Intra-gastric administration ofSmad7 antisense or sense50, 125,250, 500 μg/mouse
ileum colonproximal small
intestine
Inhibition of Smad7 by antisense DNA restores p-Smad3 and down-regulates TNBS-induced colitis
naive TNBS TNBS TNBSsense AS
Smad7p-Smad2/3
Smad3
Intestinal uptake of labelled Smad7 AS
TNBS ->ASTNBS
p<0.01
Time 0
8 hours
0.70.750.80.850.90.951
0 1 2 3 4
wei
ght c
hang
e
days
TNBS->S
*
*
Naive TNBS
TNBS + sense TNBS + AS
Smad7 antisense (AS) DNA inhibitsTh1 type cytokines in TNBS-induced colitis
0
1000
2000
3000
naive EtOH TNBS TNBS TNBS+ S +AS
IFN
-γpg
/100
μg
pro
tein
s
01020304050
IL-1
2p70
pg/2
50 μ
g p
rote
ins
0
1000
2000
3000
4000
IL-1
2p40
pg/1
00 μ
g p
rote
ins TNBS
Sense AS
T-betp-Stat1
β-actinnaive EtOH TNBS TNBS TNBS+ S +AS
naive EtOH TNBS TNBS TNBS+ S +AS
1 2 1 2
Inhibition of Smad7 by antisense DNA restores p-Smad3 and down-regulates oxazolone (oxa)-induced colitis
oxa oxa oxa ++S AS
Smad7p-Smad2/3β-actin
0,8
0,85
0,9
0,95
1
0 1 2 3days
Wei
ght c
hang
e (%
of d
ay 0
)
oxa
OXA+AS
oxa
oxa + sense
oxa + AS
0255075
100IL-4 (pg/250 μg total protein)
Naive oxa oxa+S oxa+AS
High Smad7 in established TNBS-induced colitis
TNB
S
TISSUE ANALYSIS
BALB/c mice
0 1 2 3 4
weeks
Intrarectaladministrationof TNBS (mg) 0,5 0,5 0,7 1
naiv
e
p-Smad3
naive TNBSSmad7
β-actin
Smad7 antisense oligonucleotidedown-regulates established TNBS-induced colitis
days
body
wei
ght c
hang
e (%
ofd
ay 0
)
TNBS+AS
TNBS+Sense90
92
94
96
98
100
102
104
0 1 2 3 6
4th TNBS administration
Oligoadministration
sense
antisense
Francesco PalloneGiovanna Del Vecchio BlancoIvan MonteleoneDaniele FinaRoberta CarusoLivia Biancone Massimo FantiniAngelamaria RizzzoMassimiliano SarraCarmine StolfiFlavio CaprioliUniversity “Tor Vergata”, Rome
Giampiero PalmieriAlfredo ColantoniSerena Battista Luigi Giusto Spagnoli University “Tor Vergata”, Rome
Markus NeurathUniversity of Mainz, Germany
Jelena MannDerek MannSylvia PenderUniversity of Southampton (UK)
Sergio BernardiniSabrina BalleriniGiorgio FedericiUniversity “Tor Vergata”, Rome
Monica BoirivantClaudia Di Giacinto, Mariarosaria MarinaroIstituto Superiore di Sanita’, Rome
Giuliani SpA, MilanBMRP Foundation, Los Angeles
Thomas T MacDonaldBarts and the London School of Medicine and Dentistry, London, UK.
Warren StroberNIH, Bethesda, MD, USA
MMP-3
MMP-3
β-actinMuc
osa
Supe
rnat
ant
IgGPatient 1 Patient 2
aTGFβ
0
4
IgG aTGFβ
8
12 p<0.001
0
4
8
12 p<0.001
MM
P-3
(a.u
.)M
MP-
3/β-
actin
(a.u
.)
TIMP-1
TIMP-1
Blockade of TGF-β1 reduces MMP-3 production in organ cultures of normal colonic mucosal explants
IgG aTGFβ
IgG aTGFβ IgG aTGFβPatient 1 Patient 2
TIM
P-1/β-
actin
(a.u
.)
IgG aTGFβ
IgG aTGFβ IgG aTGFβ
TIM
P-1
(a.u
.)
2
4
6
8
0
4
8
12